ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Senescence-Inducing Therapy Sequential NIR-II Mild Photothermal/Senolytic Therapy of Triple Negative Breast Cancer.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Senogenic-senolytic treatment strategies enhance tumor control and can improve survival in murine cancer models: a systematic review.BMC cancer · 2026Pooled it
- Design of benzo[1,2-b:4,3-b']dithiophene-4,5-dione based donor-acceptor-donor small molecules for efficient near-infrared photothermal therapy.Communications chemistry · 2026Article
- The drug discovery and therapeutic nano-strategies targeting cellular senescence.Materials today. Bio · 2025Review
- Senescence-Inducing Therapy Sequential NIR-II Mild Photothermal/Senolytic Therapy of Triple Negative Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Targeting the limited therapeutic options and frequent drug resistance in triple negative breast cancer (TNBC) remains a critical clinical challenge. Here, a novel sequential theranostic mild strategy leveraging cellular senescence to enhance mild photothermal therapy (PTT) and promote TNBC eradication is presented. Palbociclib, a clinically-approved CDK4/6 inhibitor, is used to induce senescence in a murine TNBC model, resulting in both tumor growth arrest and increased heat sensitivity due to HSP70 downregulation. Capitalizing on this vulnerability, an NIR-II theranostic nanoplatform (IQ NPs) composed of the photothermal agent IR1061 and the senolytic quercetin (Qu), fabricated via nanoprecipitation is developed. IQ NPs demonstrated enhanced mild PTT efficacy, further potentiated by Qu-mediated HSP70 suppression and augmented senolysis. This findings highlight the potential of exploiting senescence-inducing vulnerabilities to amplify mild PTT efficacy, providing a promising new therapeutic avenue for this aggressive and recalcitrant malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.